GAM
NBIX icon

Gemmer Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Gemmer Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-41
Closed -$4K – 1380
2021
Q2 		$4K Buy
+41
New +$3.93K ﹤0.01% 1196
2019
Q4 		– Sell
-2
Closed – – 1406
2019
Q3 		$0 Buy
+2
New +$187 ﹤0.01% 1443

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Gemmer Asset Management's NBIX Position: Q3 2021 in Review

Gemmer Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 41 shares — an estimated $4K sold.

Gemmer Asset Management first reported a position in NBIX in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Gemmer Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Gemmer Asset Management sold 41 Neurocrine Biosciences shares in Q3 2021, an estimated $4K.
  • Gemmer Asset Management first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 2 quarters.
  • Gemmer Asset Management's Neurocrine Biosciences position peaked at $4K in Q2 2021.
  • 395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Gemmer Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.